145 related articles for article (PubMed ID: 23298577)
41. Glutaraldehyde cross-linked chitosan microspheres for controlled delivery of zidovudine.
Nayak UY; Gopal S; Mutalik S; Ranjith AK; Reddy MS; Gupta P; Udupa N
J Microencapsul; 2009 May; 26(3):214-22. PubMed ID: 18819029
[TBL] [Abstract][Full Text] [Related]
42. Poly(HEMA-Zidovudine) conjugate: a macromolecular pro-drug for improvement in the biopharmaceutical properties of the drug.
Neeraj A; Chandrasekar MJ; Sara UV; Rohini A
Drug Deliv; 2011 May; 18(4):272-80. PubMed ID: 21110710
[TBL] [Abstract][Full Text] [Related]
43. Development and characterization of sulfasalazine loaded fucosylated PPI dendrimer for the treatment of cytokine-induced liver damage.
Gupta R; Mehra NK; Jain NK
Eur J Pharm Biopharm; 2014 Apr; 86(3):449-58. PubMed ID: 24189499
[TBL] [Abstract][Full Text] [Related]
44. Surface structured liposomes for site specific delivery of an antiviral agent-indinavir.
Dubey V; Nahar M; Mishra D; Mishra P; Jain NK
J Drug Target; 2011 May; 19(4):258-69. PubMed ID: 20604740
[TBL] [Abstract][Full Text] [Related]
45. Dense shell glycodendrimers as potential nontoxic anti-amyloidogenic agents in Alzheimer's disease. Amyloid-dendrimer aggregates morphology and cell toxicity.
Klementieva O; Benseny-Cases N; Gella A; Appelhans D; Voit B; Cladera J
Biomacromolecules; 2011 Nov; 12(11):3903-9. PubMed ID: 21936579
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Boyd BJ; Krippner GY; Williams ED; Porter CJ
Mol Pharm; 2009; 6(4):1190-204. PubMed ID: 19453158
[TBL] [Abstract][Full Text] [Related]
47. Genotoxicity of poly(propylene imine) dendrimers.
Ziemba B; Matuszko G; Appelhans D; Voit B; Bryszewska M; Klajnert B
Biopolymers; 2012 Aug; 97(8):642-8. PubMed ID: 22605555
[TBL] [Abstract][Full Text] [Related]
48. Attenuation of beta-amyloid-induced toxicity by sialic-acid-conjugated dendrimers: role of sialic acid attachment.
Patel DA; Henry JE; Good TA
Brain Res; 2007 Aug; 1161():95-105. PubMed ID: 17604005
[TBL] [Abstract][Full Text] [Related]
49. PEGylated elastic liposomal formulation for lymphatic targeting of zidovudine.
Jain S; Tiwary AK; Jain NK
Curr Drug Deliv; 2008 Oct; 5(4):275-81. PubMed ID: 18855596
[TBL] [Abstract][Full Text] [Related]
50. Hyperbranched dendritic nano-carriers for topical delivery of dithranol.
Agrawal U; Mehra NK; Gupta U; Jain NK
J Drug Target; 2013 May; 21(5):497-506. PubMed ID: 23594093
[TBL] [Abstract][Full Text] [Related]
51. Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice.
Singh P; Gupta U; Asthana A; Jain NK
Bioconjug Chem; 2008 Nov; 19(11):2239-52. PubMed ID: 18950215
[TBL] [Abstract][Full Text] [Related]
52. Dendrimers as versatile platform in drug delivery applications.
Svenson S
Eur J Pharm Biopharm; 2009 Mar; 71(3):445-62. PubMed ID: 18976707
[TBL] [Abstract][Full Text] [Related]
53. Influence of molecular architecture of polyether-co-polyester dendrimers on the encapsulation and release of methotrexate.
Dhanikula RS; Hildgen P
Biomaterials; 2007 Jul; 28(20):3140-52. PubMed ID: 17428531
[TBL] [Abstract][Full Text] [Related]
54. Synthesis, drug release and anti-HIV activity of a series of PEGylated zidovudine conjugates.
Li W; Wu J; Zhan P; Chang Y; Pannecouque C; De Clercq E; Liu X
Int J Biol Macromol; 2012 May; 50(4):974-80. PubMed ID: 22390847
[TBL] [Abstract][Full Text] [Related]
55. Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole.
Mansuri S; Kesharwani P; Tekade RK; Jain NK
Eur J Pharm Biopharm; 2016 May; 102():202-13. PubMed ID: 26563727
[TBL] [Abstract][Full Text] [Related]
56. Self-assemblies of 5'-cholesteryl-ethyl-phosphoryl zidovudine.
Du L; Jia J; Ge P; Jin Y
Colloids Surf B Biointerfaces; 2016 Dec; 148():385-391. PubMed ID: 27636322
[TBL] [Abstract][Full Text] [Related]
57. Influence of fourth generation poly(propyleneimine) dendrimers on blood cells.
Ziemba B; Halets I; Shcharbin D; Appelhans D; Voit B; Pieszynski I; Bryszewska M; Klajnert B
J Biomed Mater Res A; 2012 Nov; 100(11):2870-80. PubMed ID: 22623362
[TBL] [Abstract][Full Text] [Related]
58. Inclusion complexes of isoflavones with two commercially available dendrimers: Solubility, stability, structures, release behaviors, cytotoxicity, and anti-oxidant activities.
Zhao C; Wang Y; Su Y; Zhang H; Ding L; Yan X; Zhao D; Shao N; Ye X; Cheng Y
Int J Pharm; 2011 Dec; 421(2):301-9. PubMed ID: 22001794
[TBL] [Abstract][Full Text] [Related]
59. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex.
Patri AK; Kukowska-Latallo JF; Baker JR
Adv Drug Deliv Rev; 2005 Dec; 57(15):2203-14. PubMed ID: 16290254
[TBL] [Abstract][Full Text] [Related]
60. Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient.
Asthana A; Chauhan AS; Diwan PV; Jain NK
AAPS PharmSciTech; 2005 Oct; 6(3):E536-42. PubMed ID: 16354015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
